Exelixis (Exelixis) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 26, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Exelixis Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Exelixis's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Exelixis's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Exelixis's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exelixis's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Exelixis's Margin of Safety % (DCF Earnings Based) falls into.

Exelixis Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Exelixis's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (Exelixis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

EX9:Germany EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Executives

Patrick J. Haley	officer: Sr. Vice President, Commercial	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel	officer: EVP and General Counsel	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson	director	590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab	officer: CSO/EVP Disc & Trans Research	EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson	officer: EVP Prod Dev & Med Aff & CMO	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner	officer: EVP and CFO	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp	director, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski	director	SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber	director	3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum	director	C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb	officer: EVP, Discovery Research & CSO	PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste	director	515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey	director	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083